Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?
Recent Articles
Fathers (and Mothers) of Hematology
In 1963, Boston hematologist William Dameshek wrote an essay in the journal he’d founded 17 years earlier, Blood, describing 18th-century English anatomist William Hewson’s detailed...
Pretransplant Bridging With Blinatumomab Reduces MRD in Children With B-Cell Acute Lymphocytic Leukemia
In a study of children with B-cell acute lymphocytic leukemia (B-ALL) who are about to undergo allogeneic hematopoietic cell transplantation (alloHCT), bridging with blinatumomab...
Possible Delays for Landmark Opioid Trial, U.S. Judge Denies Drug Companies’ Dismissals
A growing list of drug makers, pharmacies, and distributors are facing lawsuits by states, counties, individuals, and municipalities for their roles in the opioid...
Current Issue
September 2019, Volume 5, Issue 11
This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.
